TY - JOUR
T1 - Diagnosis of hypersensitivity pneumonitis in adults
T2 - An official ATS/JRS/ALAT clinical practice guideline
AU - American Thoracic Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax
AU - Raghu, Ganesh
AU - Wilson, Kevin C.
AU - Bargagli, Elena
AU - Bendstrup, Elisabeth
AU - Chami, Hassan A.
AU - Chua, Abigail T.
AU - Chung, Jonathan H.
AU - Collins, Bridget F.
AU - Corte, Tamera J.
AU - Dalphin, Jean Charles
AU - Danoff, Sonye K.
AU - Diaz, Javier Mendoza
AU - Duggal, Abhijit
AU - Egashira, Ryoko
AU - Ewing, Thomas
AU - Gulati, Mridu
AU - Inoue, Yoshikazu
AU - Jenkins, Alex R.
AU - Johannson, Kerri A.
AU - Johkoh, Takeshi
AU - Kitaichi, Masanori
AU - Knight, Shandra L.
AU - Koschel, Dirk
AU - Kreuter, Michael
AU - Lederer, David J.
AU - Mageto, Yolanda
AU - Maier, Lisa A.
AU - Matiz, Carlos
AU - Morell, Ferran
AU - Myers, Jeffrey L.
AU - Nicholson, Andrew G.
AU - Patolia, Setu
AU - Pereira, Carlos A.
AU - Remy, Martine Jardin
AU - Renzoni, Elisabetta A.
AU - Ryerson, Christopher J.
AU - Salisbury, Margaret L.
AU - Selman, Moises
AU - Tamae, Maximiliano Kakazu
AU - Vasakova, Martina
AU - Walsh, Simon L.F.
AU - Wuyts, Wim A.
N1 - Funding Information:
Supported by the American Thoracic Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax.
Funding Information:
Author Disclosures: G.R. served as a consultant for Bellerophon, Biogen, BMS, Boehringer Ingelheim, Fibrogen, Genentech, Gilead, Nitto, Promedior, Pure Tech Health, Respivant, Roche, Veracyte, and Zambon; and served on a data and safety monitoring board for Avalyn. K.C.W. is employed by the American Thoracic Society as Chief of Documents and Documents Editor with interest in the success of ATS guidelines. H.A.C. served on an advisory committee for AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, and Pfizer; served as a speaker for Mundipharma, Novartis, and Pfizer; and received research support from Pfizer. J.H.C. served as a consultant for Veracyte; served as a speaker for Boehringer Ingelheim and Genentech; and received author royalties from Elsevier. T.J.C. served on an advisory committee for Ad Alta, Boehringer Ingelheim, Bristol Myers Squibb, Promedior, and Roche; served as a consultant for Boehringer Ingelheim and Roche; and received research support from Actelion, Avalyn Pharma, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Galapagos, and Roche. J.-C.D. served on an advisory committee for Chiesi, Novartis, and Teva; served as a speaker for Boehringer Ingelheim and Menarini; received research support from Asten France and SOS Oxygene; and received other transfers of value from GlaxoSmithKline, Novartis, and Roche. S.K.D. received research support from Boehringer Ingelheim and Genentech/Roche; served on a data and safety monitoring board for Galapagos and Galecto; and is an employee of the Pulmonary Fibrosis Foundation. R.E. served as a speaker for AstraZeneca, Bayer, Boehringer Ingelheim, and Shionogi. M.G. served on an advisory committee and received other transfers of value from Boehringer Ingelheim and the France Foundation; received research support from Boehringer Ingelheim; and received travel expenses from the Pulmonary Fibrosis Foundation. Y.I. served as a consultant for Boehringer Ingelheim and Promedior; served on an advisory committee for Asahi Kasei, Galapagos, and Shionogi; received research support from Sekisui Medical; and received honoraria from Boehringer Ingelheim and Shionogi. K.A.J. served on an advisory committee for Blade Therapeutics, Boehringer Ingelheim, Roche, and Theravance; served as a consultant for Blade Therapeutics, Boehringer Ingelheim, Theravance, and Three Lakes Foundation; served as a speaker for Boehringer Ingelheim and Roche; and received research support from UCB. D.K. served on an advisory committee and received research support from Boehringer Ingelheim and Roche. M. Kreuter served on an advisory committee for Boehringer Ingelheim, Galapagos, and Roche; and received research support from Boehringer Ingelheim and Roche. D.J.L. served on an advisory committee for Boehringer Ingelheim; served as a consultant for Galapagos, Galecto, Genentech/Roche, Patara, Pulmonary Fibrosis Foundation, and Veracyte; and is an employee of Regeneron. Y.M. received honoraria from Boehringer Ingelheim and Genentech. C.M. received research support from AstraZeneca, Boehringer Ingelheim, Celgene, Merck, and Sanofi; and his spouse is an employee of Merck. A.G.N. served as a consultant for eResearch Technology and MedQIA; and served as a speaker for Boehringer Ingelheim. E.A.R. served on an advisory committee for Roche; served as a speaker for Boehringer Ingelheim, Mundipharma, and Roche; and received travel support from Boehringer Ingelheim. C.J.R. received research support and served as a speaker for Boehringer Ingelheim and Roche. M.L.S. served on an advisory committee, served as a speaker, and received research support from Boehringer Ingelheim; and served as a consultant for Boehringer Ingelheim and Orinove. M.S. served as a consultant for Boehringer Ingelheim and Celgene. M.V. served on an advisory committee and as a consultant for Boehringer Ingelheim; and received research support from Roche. S.L.F.W. served on an advisory committee for Boehringer Ingelheim and Roche; served as a consultant for Galapagos, OSIC, and Sanofi; served as a speaker for Bracco; and received research support from Boehringer Ingelheim. W.A.W. received research support from Boehringer Ingelheim and Roche. E. Bargagli, E. Bendstrup, A.T.C., B.F.C., J.D.-M., A.D., T.E., A.R.J., T.J., M. Kitaichi, S.L.K., L.A.M., F.M., J.L.M., S.P., C.A.P., M.R.-J., and M.T.-K. reported no relationships with relevant commercial interests.
Publisher Copyright:
Copyright © 2020 by the American Thoracic Society.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Background: This guideline addresses the diagnosis of hypersensitivity pneumonitis (HP). It represents a collaborative effort among the American Thoracic Society, Japanese Respiratory Society, and Asociación Latinoamericana del Tórax. Methods: Systematic reviews were performed for six questions. Theevidencewas discussed, andthenrecommendations were formulated by amultidisciplinary committee of experts in the field of interstitial lung disease and HP using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. Results: The guideline committee defined HP, and clinical, radiographic, andpathological features were described.HPwas classified into nonfibrotic and fibrotic phenotypes. There was limited evidence that was directly applicable to all questions. The need for a thorough history and a validated questionnaire to identify potential exposureswas agreed on. Serum IgG testing against potential antigens associated with HP was suggested to identify potential exposures. For patients with nonfibrotic HP, a recommendation was made in favor of obtaining bronchoalveolar lavage (BAL) fluid for lymphocyte cellular analysis, and suggestions for transbronchial lung biopsy and surgical lung biopsywere also made. For patients with fibrotic HP, suggestionsweremade in favor of obtaining BAL for lymphocyte cellular analysis, transbronchial lung cryobiopsy, and surgical lung biopsy. Diagnostic criteria were established, and a diagnostic algorithmwas created by expert consensus. Knowledge gaps were identified as future research directions. Conclusions: The guideline committee developed a systematic approach to the diagnosis of HP. The approach should be reevaluated as new evidence accumulates.
AB - Background: This guideline addresses the diagnosis of hypersensitivity pneumonitis (HP). It represents a collaborative effort among the American Thoracic Society, Japanese Respiratory Society, and Asociación Latinoamericana del Tórax. Methods: Systematic reviews were performed for six questions. Theevidencewas discussed, andthenrecommendations were formulated by amultidisciplinary committee of experts in the field of interstitial lung disease and HP using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. Results: The guideline committee defined HP, and clinical, radiographic, andpathological features were described.HPwas classified into nonfibrotic and fibrotic phenotypes. There was limited evidence that was directly applicable to all questions. The need for a thorough history and a validated questionnaire to identify potential exposureswas agreed on. Serum IgG testing against potential antigens associated with HP was suggested to identify potential exposures. For patients with nonfibrotic HP, a recommendation was made in favor of obtaining bronchoalveolar lavage (BAL) fluid for lymphocyte cellular analysis, and suggestions for transbronchial lung biopsy and surgical lung biopsywere also made. For patients with fibrotic HP, suggestionsweremade in favor of obtaining BAL for lymphocyte cellular analysis, transbronchial lung cryobiopsy, and surgical lung biopsy. Diagnostic criteria were established, and a diagnostic algorithmwas created by expert consensus. Knowledge gaps were identified as future research directions. Conclusions: The guideline committee developed a systematic approach to the diagnosis of HP. The approach should be reevaluated as new evidence accumulates.
KW - Fibrotic hypersensitivity pneumonitis
KW - Hypersensitivity pneumonitis
KW - Interstitial lung disease
KW - Nonfibrotic hypersensitivity pneumonitis
KW - Pulmonary fibrosis
UR - http://www.scopus.com/inward/record.url?scp=85089126056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089126056&partnerID=8YFLogxK
U2 - 10.1164/rccm.202005-2032ST
DO - 10.1164/rccm.202005-2032ST
M3 - Review article
C2 - 32706311
AN - SCOPUS:85089126056
SN - 1073-449X
VL - 202
SP - E36-E69
JO - American journal of respiratory and critical care medicine
JF - American journal of respiratory and critical care medicine
IS - 3
ER -